Biography
There are general principles of cancer care that have withstood the test of time. However, scientific and technologic advances are being made rapidly. As an oncologist, I always remember that a patient is at the end of every stethoscope, robot, sequencing machine and so on.
I chose this field because it is most interdisciplinary and dynamic – plus, I work with a team of outstanding colleagues. I have a special interest in what was once called tumor immunology, now referred to as immuno-oncology.
Conditions I Treat
- Melanoma
- Prostate cancer
- Urinary cancer
- Bladder cancer
- Kidney cancer
- Testicular cancer
- Penile cancer
- Sarcomas
- Rare cancers such as Merkel cell carcinoma and Kaposi's sarcoma
Professional Background
Deepak Sahasrabudhe is a Professor of Medicine in the Division of Hematology/Oncology at the James P. Wilmot Cancer Center at the University of Rochester School of Medicine and Dentistry in Rochester, New York. Dr. Sahasrabudhe received his training at Albany Medical Center Hospital in Albany, New York and the University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Dr. Sahasrabudhe is a key teaching faculty member in the Hematology/Oncology Fellowship Program. He has mentored several fellows over the last 17 years.
Dr. Sahasrabudhe's clinical research interest is in urologic malignancies. He also sees patients with melanomas and sarcomas.
Dr. Sahasrabudhe is a member of many national professional organizations including the American College of Physicians, the American Association for Cancer Research, and the American Society of Clinical Oncology.
Clinical Trials
Serologic Response to the SARS-CoV-2 mRNA-1273 Vaccine in Select Subsets of Oncology Patients - A Pilot Study
Lead Researcher: Deepak Madhao Sahasrabudhe MD
To explore the immune response to the COVID-19 vaccine in cancer patients and compare to the general population.
View Study Details
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
Lead Researcher: Deepak Madhao Sahasrabudhe MD
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body. The addition of cabozantinib to the usual treatment may make it work better. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known how well the combination of cabozantinib and nivolumab after initial treatment with ipilimumab and nivolumab works in treating patients with renal cell cancer that has spread to other parts of the body.
View Study Details
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies (MK6482-005)
Lead Researcher: Deepak Madhao Sahasrabudhe MD
The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS.
View Study Details
A Pilot Study of Cisplatin in Castration Resistant Prostate Cancer That is Becoming Refractory to Enzalutamide
Lead Researcher: Deepak Madhao Sahasrabudhe MD
It is hypothesized that treatment with cisplatin will reverse emerging refractoriness to enzalutimide in patients with CRPC by affecting AR function.
View Study Details
Publications
Journal Articles
6/2018
Dineen M, Hansen E, Guancial E, Sievert L, Sahasrabudhe D. "Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature." Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.. 2018 Jun 0; 24(4):314-318. Epub 2017 Mar 29.
5/20/2018
Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB, . "Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2018 May 20; 36(15):1505-1512. Epub 2018 Apr 04.
11/2016
Pan C, Singh S, Sahasrabudhe DM, Chakkalakal JV, Krolewski JJ, Nastiuk KL. "TGF? Superfamily Members Mediate Androgen Deprivation Therapy-Induced Obese Frailty in Male Mice." Endocrinology.. 2016 Nov 0; 157(11):4461-4472. Epub 2016 Sep 09.
Books & Chapters
2001
Chapter Title: Soft Tissue Sarcoma
Book Title: Clinical Oncology, 8th Edition
Author List: Spiro, IJ; Suit, HD; Rosier, RN; Sahasrabudhe, DM
Edited By: Rubin P.
Published By: W.B. Saunders Company, Harcourt Brace Jovanovich Inc 2001 in Philadelphia PA
2001
Chapter Title: Bone Tumors
Book Title: Clinical Oncology, 8th Edition
Author List: Rosier, RN; O'Keefe, RJ; Sahasrabudhe, DM
Edited By: Rubin P.
Published By: W.B. Saunders Company, Harcourt Brace Jovanovich, Inc 2001 in Philadelphia PA
VIEW ALL PUBLICATIONS